GO:0008109 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008109 describes the enzymatic activity that transfers N-acetylglucosamine to a galactose residue on N-acetyllactosamine, forming a beta-1,6 branch.
• This activity is responsible for the biosynthesis of the blood group I antigen and midchain branching of oligo(N-acetyllactosaminoglycans) [5,8].
• The enzyme is encoded by the GCNT2 gene (also known as IGnT) in humans, and its deficiency leads to the i blood group phenotype.
• Altered beta-1,6-N-acetylglucosaminyltransferase activity is linked to cancer metastasis and TGF-beta signaling.
• Bovine herpesvirus 4 modulates its own beta-1,6-N-acetylglucosaminyltransferase activity through alternative splicing, highlighting viral exploitation of this activity.
• Studying GO:0008109 requires glycan analysis, enzyme assays, and CRISPR-based models to dissect its roles in development and disease.
Description
N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity (GO:0008109) is a molecular function that catalyzes the transfer of N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to the galactose moiety of a beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl derivative, creating a beta-1,6 linkage. This reaction is a key step in the biosynthesis of branched polylactosamine structures, which are essential for various biological recognition processes. The activity was first described in Novikoff ascites tumor cells, where both beta-1,3 and beta-1,6 N-acetylglucosaminyltransferase activities were detected. Since then, it has been found in human serum and urine, and its product, the I antigen, is a classic marker of human blood group antigens [5,6]. The enzyme responsible for this activity in humans is encoded by the GCNT2 gene (formerly known as IGnT), and its deficiency results in the rare i blood group phenotype, characterized by a lack of branched I antigen on red blood cells. Beyond blood group biology, this activity has been implicated in cancer progression, particularly in breast cancer metastasis, where it enhances TGF-beta signaling. Understanding GO:0008109 is therefore important for researchers in glycobiology, hematology, and oncology, as it provides a molecular handle on how glycan branching influences cell-cell interactions and signaling.
N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity At A Glance
| GO ID | GO:0008109 |
|---|---|
| GO term | N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity |
| Ontology | molecular_function |
| Synonym | galbeta1->4GlcNAc-R beta1->6 N-acetylglucosaminyltransferase activity; N-acetylglucosaminyltransferase activity; UDP-GlcNAc:Gal-R, beta-D-6-N-acetylglucosaminyltransferase activity |
| Major function | Transfer of GlcNAc to N-acetyllactosamine to form beta-1,6 branches in glycans |
| Reaction | beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl derivative + UDP-N-acetyl-alpha-D-glucosamine = N-acetyl-beta-D-glucosaminyl-1,6-beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl derivative + UDP + H+ |
| Cofactors | Divalent cations such as Mn2+ are typically required for glycosyltransferase activity (inferred from related enzymes) |
| Subcellular location | Golgi apparatus (typical for glycosyltransferases) |
| Representative gene | GCNT2 (IGnT) in humans |
What Is GO:0008109?
GO:0008109 is defined as the catalysis of the reaction: a beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl derivative + UDP-N-acetyl-alpha-D-glucosamine = an N-acetyl-beta-D-glucosaminyl-1,6-beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl derivative + UDP + H+. In simpler terms, it is an enzyme activity that adds a GlcNAc sugar in a beta-1,6 linkage to a specific galactose-containing acceptor, thereby creating a branch point in glycan chains.
Why Is N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity Important in Cell Biology?
GO:0008109 is important because it governs the synthesis of branched polylactosamine structures that are critical for cell surface recognition, including blood group I antigen expression and midchain branching of oligo(N-acetyllactosaminoglycans) [5,8]. Dysregulation of this activity has been linked to cancer metastasis and altered TGF-beta signaling, making it a potential target for therapeutic intervention. Additionally, viruses such as bovine herpesvirus 4 can modulate this activity through alternative splicing, indicating its relevance in host-pathogen interactions.
• Defines the biosynthetic step for blood group I antigen, a key marker in transfusion medicine.
• Responsible for midchain branching of oligo(N-acetyllactosaminoglycans), affecting glycan complexity.
• Enhances breast cancer metastasis and TGF-beta signaling, suggesting a role in tumor progression.
• Modulated by bovine herpesvirus 4 via alternative splicing, highlighting viral immune evasion strategies.
• Detected in human serum and urine, indicating potential as a biomarker [5,6].
• First characterized in Novikoff ascites tumor cells, linking it to cancer biology.
• Deficiency causes the rare i blood group phenotype, important for genetic counseling.
• Plays a role in O-mannosyl glycan biosynthesis in mammals, though distinct from beta-1,2 activity.
• May be involved in Alzheimer's disease-like pathologies through related glycosylation pathways.
• Provides a target for glycoengineering and CRISPR-based studies of glycosylation.
What Happens During N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs the sugar donor and the acceptor molecule.
The enzyme binds UDP-N-acetylglucosamine (UDP-GlcNAc) as the donor substrate and a beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl derivative as the acceptor. This acceptor is typically part of a polylactosamine chain on glycoproteins or glycolipids. The binding specificity ensures that only acceptors with a terminal beta-galactose are used, as demonstrated in studies of human serum enzymes.
Catalytic transfer and branch formation
In simple terms: The enzyme attaches GlcNAc to the acceptor, creating a branch.
The catalytic mechanism involves the transfer of GlcNAc from UDP-GlcNAc to the 6-hydroxyl group of the galactose residue, forming a beta-1,6 linkage. This reaction creates a branch point in the glycan chain, converting a linear polylactosamine into a branched structure. The product is an N-acetyl-beta-D-glucosaminyl-1,6-beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl derivative, which is the defining feature of the I antigen.
Role in blood group I antigen synthesis
In simple terms: This activity builds the I antigen on red blood cells.
The beta-1,6 branch formed by this enzyme is essential for the biosynthesis of the blood group I antigen, a carbohydrate structure on red blood cells. In individuals lacking this activity, the i antigen persists, leading to the rare i blood group phenotype. The enzyme responsible is encoded by GCNT2, and its deficiency is linked to this phenotype.
Midchain branching of oligo(N-acetyllactosaminoglycans)
In simple terms: The enzyme creates branches in long sugar chains.
This activity is responsible for midchain branching of oligo(N-acetyllactosaminoglycans), which are long polylactosamine chains attached to proteins or lipids. Such branching increases the complexity and diversity of cell surface glycans, influencing cell-cell recognition and signaling. Human serum contains a novel beta-1,6-N-acetylglucosaminyltransferase that catalyzes this branching.
Viral modulation through alternative splicing
In simple terms: Some viruses can change how this enzyme works by splicing its RNA.
Bovine herpesvirus 4 encodes its own beta-1,6-N-acetylglucosaminyltransferase and modulates its activity through alternative splicing. This allows the virus to fine-tune glycan structures on infected cells, potentially evading immune detection. This highlights how pathogens can exploit GO:0008109 for their own benefit.
Key Genes Involved in GO:0008109 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity
The following genes and proteins are directly or indirectly associated with N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity (GO:0008109).
| Gene | Major Role | Research Relevance |
|---|---|---|
| GCNT2 | Encodes the enzyme responsible for beta-1,6-N-acetylglucosaminyltransferase activity; synthesizes I antigen | Mutations cause i blood group phenotype; studied in hematology and cancer |
| GCNT1 | Encodes a beta-1,6-N-acetylglucosaminyltransferase involved in core 2 O-glycan branching | Related family member; often co-expressed and studied in cancer |
| GCNT3 | Encodes a beta-1,6-N-acetylglucosaminyltransferase for core 2 and core 4 O-glycans | Implicated in mucin-type O-glycosylation and cancer |
| GCNT4 | Encodes a beta-1,6-N-acetylglucosaminyltransferase for core 2 O-glycans | Potential role in immune cell glycosylation |
| B3GNT2 | Beta-1,3-N-acetylglucosaminyltransferase that can compete with beta-1,6 activity | Modifies polylactosamine chains; studied in cancer |
| B3GNT3 | Beta-1,3-N-acetylglucosaminyltransferase | Related to beta-1,6 branching pathways |
| B4GALT1 | Beta-1,4-galactosyltransferase that creates acceptor for beta-1,6 branching | Provides substrate for GCNT2; studied in glycan biosynthesis |
| B4GALT2 | Beta-1,4-galactosyltransferase | Similar to B4GALT1; contributes to acceptor synthesis |
| ST3GAL1 | Sialyltransferase that can cap glycans and prevent branching | Regulates availability of acceptor for beta-1,6 branching |
| ST6GAL1 | Alpha-2,6-sialyltransferase | Modifies glycans and may influence branching |
| FUT8 | Fucosyltransferase that adds fucose to N-glycans | Cross-talk with branching pathways |
| MGAT5 | Alpha-1,6-mannosylglycoprotein beta-1,6-N-acetylglucosaminyltransferase | Distinct enzyme but similar beta-1,6 linkage on N-glycans |
| POMGNT1 | Protein O-linked mannose beta-1,2-N-acetylglucosaminyltransferase 1 | Related glycosyltransferase in O-mannosyl glycan synthesis [2,3] |
| POMGNT2 | Protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase 2 | Another O-mannosyl glycan enzyme |
| B3GALNT2 | Beta-1,3-N-acetylgalactosaminyltransferase | Involved in O-mannosyl glycan biosynthesis |
| LARGE1 | Xylosyl- and glucuronyltransferase | Modifies O-mannosyl glycans; related to muscular dystrophy |
| FKRP | Fukutin-related protein | Glycosyltransferase-like; involved in dystroglycanopathy |
| B4GAT1 | Beta-1,4-glucuronyltransferase | Related to glycosaminoglycan synthesis |
How Is N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity Regulated?
The activity of N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase is regulated at multiple levels. Expression of the GCNT2 gene is controlled by alternative splicing, producing multiple isoforms with different tissue distributions. In cancer, TGF-beta signaling can induce GCNT2 expression, leading to increased beta-1,6 branching and enhanced metastatic potential. Additionally, the availability of donor and acceptor substrates, as well as competition from other glycosyltransferases such as beta-1,3-N-acetylglucosaminyltransferases, can modulate the overall activity [1,5]. Viral proteins can also regulate the enzyme through alternative splicing, as seen in bovine herpesvirus 4.
N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GCNT2 | i blood group phenotype; cancer metastasis | Knockout mice; human cell lines with GCNT2 KO |
| GCNT1 | Cancer, immune disorders | Overexpression in cancer cell lines; KO in T cells |
| POMGNT1 | Alzheimer's disease-like pathologies; muscular dystrophy | KO mice; patient-derived iPSCs |
| B4GALT1 | Congenital disorder of glycosylation | Point mutation knock-in in cell lines |
| MGAT5 | Cancer, autoimmune diseases | Knockout mice; CRISPR KO in tumor models |
Blood group i phenotype
Deficiency of beta-1,6-N-acetylglucosaminyltransferase activity in the liver of LEC rats leads to the loss of blood group I antigen and persistence of the i antigen. This rare phenotype is caused by mutations in the GCNT2 gene and is important in transfusion medicine and genetic studies.
Breast cancer metastasis
Engagement of I-branching beta-1,6-N-acetylglucosaminyltransferase 2 (GCNT2) in breast cancer enhances metastasis and TGF-beta signaling. High expression of this enzyme correlates with poor prognosis, making it a potential therapeutic target.
Viral pathogenesis
Bovine herpesvirus 4 modulates its beta-1,6-N-acetylglucosaminyltransferase activity through alternative splicing, which may contribute to immune evasion and viral spread. This suggests that similar mechanisms could exist in human herpesviruses.
Neurodegeneration
Decreased expression of protein O-linked mannose beta-1,2-N-acetylglucosaminyltransferase 1 (POMGNT1) contributes to Alzheimer's disease-like pathologies. Although POMGNT1 is a different enzyme, it highlights the importance of glycosyltransferases in neurodegeneration, and similar roles for beta-1,6 branching enzymes are under investigation.
From N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GCNT2 loss affect blood group I antigen expression? | GCNT2 knockout in erythroleukemia cell lines (e.g., K562) |
| Does GCNT2 overexpression enhance metastasis? | GCNT2 overexpression in breast cancer cell lines (e.g., MDA-MB-231) followed by xenograft |
| What is the role of specific GCNT2 isoforms? | Isoform-specific knock-in of point mutations in GCNT2 |
| How does viral alternative splicing affect enzyme activity? | Bovine herpesvirus 4 infection of permissive cells with spliced variants |
| Can CRISPR screening identify regulators of beta-1,6 branching? | Genome-wide CRISPR library screening in glycan-engineered cells |
| Does GCNT2 deficiency alter TGF-beta signaling? | GCNT2 KO in mammary epithelial cells; phospho-SMAD assays |
How to Study the N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Catalytic transfer of GlcNAc to acceptor | Confirming GCNT2 activity in cell lysates |
| Mass spectrometry | Glycan composition and branching | Structural analysis of polylactosamines |
| CRISPR-Cas9 KO | Loss of gene function | Studying GCNT2 deficiency in cell lines |
| CRISPR knock-in | Introduction of point mutations | Dissecting catalytic residues |
| Flow cytometry | Cell surface glycan expression | Quantifying I antigen on red blood cells |
| Western blot | Protein expression levels | Validating GCNT2 overexpression or KO |
| qRT-PCR | mRNA expression | Measuring GCNT2 isoform levels |
| Lectin histochemistry | Tissue glycan distribution | Localizing branched glycans in tumors |
Enzyme activity assays
Beta-1,6-N-acetylglucosaminyltransferase activity can be measured using radioactive or fluorescently labeled acceptor substrates and UDP-GlcNAc, followed by product separation via chromatography [1,5]. These assays are essential for confirming the catalytic function of GCNT2 and its isoforms.
Glycan analysis by mass spectrometry
Mass spectrometry (MS) of released glycans can reveal the presence of beta-1,6 branches on polylactosamine chains. This method is used to assess the impact of GCNT2 knockout or overexpression on glycan structures in cells and tissues.
CRISPR-Cas9 knockout and knock-in
CRISPR-Cas9 can generate GCNT2 knockout cell lines to study loss of function, or knock-in specific point mutations to dissect catalytic residues [7,8]. These models are valuable for linking genotype to glycan phenotype.
Flow cytometry and lectin binding
Flow cytometry using lectins that recognize branched polylactosamines (e.g., I antigen) can quantify cell surface glycan changes after genetic manipulation. This is a rapid and quantitative method for assessing beta-1,6 branching.
How CRISPR Can Be Used to Study GO:0008109 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity
Knockout
CRISPR-Cas9 knockout of GCNT2 in cell lines such as K562 or MDA-MB-231 abolishes beta-1,6-N-acetylglucosaminyltransferase activity, leading to loss of I antigen and altered glycan branching. These models are used to study the consequences of enzyme deficiency in blood group biology and cancer.
Point Mutation
Introducing point mutations in the catalytic domain of GCNT2 via CRISPR can identify residues critical for substrate binding and catalysis. Such models help distinguish between loss-of-function and hypomorphic alleles.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) into the endogenous GCNT2 locus allows for precise localization and interaction studies without overexpression artifacts. This is useful for tracking isoform-specific functions.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of GCNT2 can increase beta-1,6 branching, promoting metastasis in breast cancer models. Overexpression studies help establish causality between enzyme levels and phenotypic changes.
How EDITGENE Supports N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity Research
Researchers studying N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycan branching, blood group antigen synthesis, or cancer progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity research.
Frequently Asked Questions About N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity
What is N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity?
It is an enzyme activity (GO:0008109) that transfers N-acetylglucosamine to a galactose residue on N-acetyllactosamine, forming a beta-1,6 branch in glycans.
What genes are involved in N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity?
The primary gene is GCNT2 (also known as IGnT), which encodes the enzyme responsible for this activity in humans. Related genes include GCNT1, GCNT3, and GCNT4.
What is the function of GO:0008109?
GO:0008109 catalyzes the formation of beta-1,6 branches in polylactosamine chains, which are important for blood group I antigen synthesis and cell surface recognition [5,8].
How is N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity measured?
It is typically measured using enzyme assays with radiolabeled or fluorescent acceptors, or by mass spectrometry of glycan products [1,5].
What diseases are associated with N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity?
Deficiency causes the i blood group phenotype, and increased activity is linked to breast cancer metastasis and TGF-beta signaling.
Can CRISPR be used to study GO:0008109?
Yes, CRISPR-Cas9 knockout or knock-in of GCNT2 allows researchers to study loss- or gain-of-function phenotypes related to this activity [7,8].
What is the blood group I antigen?
The I antigen is a branched polylactosamine structure on red blood cells, synthesized by the beta-1,6-N-acetylglucosaminyltransferase encoded by GCNT2.
How does bovine herpesvirus 4 modulate this activity?
Bovine herpesvirus 4 uses alternative splicing to produce different isoforms of its beta-1,6-N-acetylglucosaminyltransferase, altering its activity.
Is N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity found in human serum?
Yes, a novel beta-1,6-N-acetylglucosaminyltransferase activity involved in midchain branching has been detected in human serum.
What are the synonyms for GO:0008109?
Synonyms include galbeta1->4GlcNAc-R beta1->6 N-acetylglucosaminyltransferase activity, N-acetylglucosaminyltransferase activity, and UDP-GlcNAc:Gal-R, beta-D-6-N-acetylglucosaminyltransferase activity.
Conclusion
N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity (GO:0008109) is a fundamental enzymatic function that creates beta-1,6 branches in glycans, impacting blood group antigen synthesis, cancer progression, and viral pathogenesis [1,5,7,8]. Understanding its regulation and substrates provides insights into glycan-mediated biological processes and offers opportunities for therapeutic intervention. Researchers can leverage CRISPR-based models and advanced glycan analysis to further dissect its roles in health and disease.
References
- 1. van den Eijnden DH et al.. 1983. Novikoff ascites tumor cells contain N-acetyllactosaminide beta 1 leads to 3 and beta 1 leads to 6 N-acetylglucosaminyltransferase activity.. J Biol Chem 258(6):3435-7 PMID: 6219989
- 2. Feng Y et al.. 2022. Decreased expression of protein O-linked mannose β-1,2-N-acetylglucosaminyltransferase 1 contributes to Alzheimer's disease-like pathologies.. J Neurophysiol 127(4):1067-1074 PMID: 35320023
- 3. Takahashi S et al.. 2001. A new beta-1,2-N-acetylglucosaminyltransferase that may play a role in the biosynthesis of mammalian O-mannosyl glycans.. Glycobiology 11(1):37-45 PMID: 11181560
- 4. Lété C et al.. 2016. Bovine Herpesvirus 4 Modulates Its β-1,6-N-Acetylglucosaminyltransferase Activity through Alternative Splicing.. J Virol 90(4):2039-51 PMID: 26656682
- 5. Leppänen A et al.. 1991. Human serum contains a novel beta 1,6-N-acetylglucosaminyltransferase activity that is involved in midchain branching of oligo (N-acetyllactosaminoglycans).. Biochemistry 30(38):9287-96 PMID: 1832557
- 6. Takeya A et al.. 1985. The presence of N-acetyllactosamine and lactose: beta (1-3)N-acetylglucosaminyltransferase activity in human urine.. Jpn J Med Sci Biol 38(1):1-8 PMID: 3160874
- 7. Zhang H et al.. 2011. Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling.. Cancer Res 71(14):4846-56 PMID: 21750175
- 8. Gu J et al.. 1992. Deficiency of beta 1-6 N-acetylglucosaminyltransferase involved in the biosynthesis of blood group I antigen in the liver of LEC rats.. Jpn J Cancer Res 83(8):878-84 PMID: 1399824
